GlassScriptPhysician profile
Salomi Rami
NPI 1699202713
$6,831.91
in general payments reported to CMS, 2019-2025
42 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $469 · 2021: $1,815 · 2022: $1,159 · 2023: $1,295 · 2024: $910 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,222.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,910.42 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $898.99 | 2021-2025 | |
| Glaxosmithkline, LLC. | $800.82 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $649.84 | 2020-2025 | Krystexxa, Evenity, Repatha |
| Pfizer INC. | $383.56 | 2023-2025 | |
| Lilly USA, LLC | $366.50 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $210.75 | 2019-2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $185.61 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $137.51 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $132.44 | 2021 | |
| Astellas Pharma US INC | $132.09 | 2021-2024 | Veozah |
| Amarin Pharma, INC. | $107.06 | 2020-2022 | |
| Genzyme Corporation | $105.53 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $104.35 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.75 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salomi Rami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.